Key products, such as Darzalex and Stelara, and other core products like Invega Sustenna and new drugs, Erleada and Tremfya, contributed significantly to sales growth. The sales growth was, however, dampened by lower sales of key medicines, Imbruvica and Xarelto and generic/biosimilar competition to drugs like Zytiga and Remicade as well as lower COVID-19 vaccine sales.